{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:35:05Z","timestamp":1793018105577,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s13555-026-01936-2","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:44:20Z","timestamp":1790869460000},"page":"5389-5404","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rezpegaldesleukin and Regulatory T Cell Restoration in Immune-Mediated Skin Diseases"],"prefix":"10.1007","volume":"16","author":[{"given":"Jo\u00e3o","family":"Domingues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Chovatiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-0870","authenticated-orcid":false,"given":"Tiago","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"issue":"1","key":"1936_CR1","doi-asserted-by":"publisher","first-page":"9249","DOI":"10.1038\/s41467-024-53531-y","volume":"15","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Rosmarin D, Chovatiya R, et al. The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials. Nat Commun. 2024;15(1):9249. https:\/\/doi.org\/10.1038\/s41467-024-53531-y.","journal-title":"Nat Commun"},{"issue":"10247","key":"1936_CR2","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","volume":"396","author":"SM Langan","year":"2020","unstructured":"Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(20)31286-1.","journal-title":"Lancet"},{"key":"1936_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01384-2","author":"K Sanchez","year":"2025","unstructured":"Sanchez K, Lipner SR. Evaluating current and emergent JAK inhibitors for alopecia areata: a narrative review. Dermatol Ther (Heidelb). 2025. https:\/\/doi.org\/10.1007\/s13555-025-01384-2.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1936_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2021.100116","volume":"4","author":"N Dixit","year":"2021","unstructured":"Dixit N, Hayward NJ, Chang W, et al. NKTR-358: a novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases. J Transl Autoimmun. 2021;4:100116. https:\/\/doi.org\/10.1016\/j.jtauto.2021.100116.","journal-title":"J Transl Autoimmun"},{"issue":"4","key":"1936_CR5","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2109927.","journal-title":"N Engl J Med"},{"key":"1936_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.826587","volume":"10","author":"D Zhang","year":"2022","unstructured":"Zhang D, Liu J, Zhao X, et al. Expression of helper and regulatory T cells in atopic dermatitis: a meta-analysis. Front Pediatr. 2022;10:826587. https:\/\/doi.org\/10.3389\/fped.2022.826587.","journal-title":"Front Pediatr"},{"issue":"2","key":"1936_CR7","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1159\/000351185","volume":"227","author":"C Mattozzi","year":"2013","unstructured":"Mattozzi C, Salvi M, D\u2019Epiro S, et al. Importance of regulatory T cells in the pathogenesis of psoriasis: review of the literature. Dermatology. 2013;227(2):134\u201345. https:\/\/doi.org\/10.1159\/000351185.","journal-title":"Dermatology"},{"issue":"2","key":"1936_CR8","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.3390\/ijms24021841","volume":"24","author":"I Pietraforte","year":"2023","unstructured":"Pietraforte I, Di Fusco D, De Vitis C, et al. Autoreactive T-cells in psoriasis: are they spoiled Tregs and can therapies restore their functions? Int J Mol Sci. 2023;24(2):1841. https:\/\/doi.org\/10.3390\/ijms24021841.","journal-title":"Int J Mol Sci"},{"key":"1936_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2022.100148","volume":"5","author":"C Fanton","year":"2022","unstructured":"Fanton C, Siddhanti S, Dixit N, et al. Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus. J Transl Autoimmun. 2022;5:100148. https:\/\/doi.org\/10.1016\/j.jtauto.2022.100148.","journal-title":"J Transl Autoimmun"},{"issue":"2","key":"1936_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.immuni.2010.08.004","volume":"33","author":"TR Malek","year":"2010","unstructured":"Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity. 2010;33(2):153\u201365. https:\/\/doi.org\/10.1016\/j.immuni.2010.08.004.","journal-title":"Immunity"},{"issue":"25","key":"1936_CR11","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aat1482","volume":"3","author":"AK Abbas","year":"2018","unstructured":"Abbas AK, Trotta E, Simeonov DR, Marson A, Bluestone JA. Revisiting IL-2: biology and therapeutic prospects. Sci Immunol. 2018;3(25):eaat1482. https:\/\/doi.org\/10.1126\/sciimmunol.aat1482.","journal-title":"Sci Immunol"},{"key":"1936_CR12","doi-asserted-by":"publisher","first-page":"1243556","DOI":"10.3389\/fimmu.2023.1243556","volume":"14","author":"T Passeron","year":"2023","unstructured":"Passeron T, Renert-Yuval Y, Maari C, et al. Inhibition of T-cell activity in alopecia areata: recent developments and new directions. Front Immunol. 2023;14:1243556. https:\/\/doi.org\/10.3389\/fimmu.2023.1243556.","journal-title":"Front Immunol"},{"issue":"97","key":"1936_CR13","doi-asserted-by":"publisher","first-page":"eadk6116","DOI":"10.1126\/sciimmunol.adk6116","volume":"9","author":"JN Cohen","year":"2024","unstructured":"Cohen JN, Gouirand V, Bhatt DL, et al. Regulatory T cells in skin mediate immune privilege of the hair follicle stem cell niche. Sci Immunol. 2024;9(97):eadk6116. https:\/\/doi.org\/10.1126\/sciimmunol.adk6116.","journal-title":"Sci Immunol"},{"issue":"4","key":"1936_CR14","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/j.1365-2133.2011.10744.x","volume":"166","author":"C Luci","year":"2012","unstructured":"Luci C, Gaudy-Marqueste C, Trinh A, et al. Peripheral natural killer cells exhibit qualitative and quantitative changes in patients with psoriasis and atopic dermatitis. Br J Dermatol. 2012;166(4):789\u201396. https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10744.x.","journal-title":"Br J Dermatol"},{"issue":"539","key":"1936_CR15","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay1005","volume":"12","author":"MR Mack","year":"2020","unstructured":"Mack MR, Kim BS. Blood natural killer cell deficiency reveals an immunotherapy strategy for atopic dermatitis. Sci Transl Med. 2020;12(539):eaay1005. https:\/\/doi.org\/10.1126\/scitranslmed.aay1005.","journal-title":"Sci Transl Med"},{"issue":"1","key":"1936_CR16","doi-asserted-by":"publisher","first-page":"kyad012","DOI":"10.1093\/discim\/kyad012","volume":"2","author":"M Lee","year":"2023","unstructured":"Lee M, Shi X, Barber DL, et al. CD56bright natural killer cells preferentially kill proliferating CD4+ T cells. Discov Immunol. 2023;2(1):kyad012. https:\/\/doi.org\/10.1093\/discim\/kyad012.","journal-title":"Discov Immunol"},{"key":"1936_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(26)01143-8","author":"JI Silverberg","year":"2026","unstructured":"Silverberg JI, Rosmarin D, Bieber T, et al. Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study. Lancet. 2026. https:\/\/doi.org\/10.1016\/S0140-6736(26)01143-8.","journal-title":"Lancet"},{"key":"1936_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae266.102","author":"MJ Gooderham","year":"2024","unstructured":"Gooderham MJ, Lynde C, Alam M, et al. A phase 2b randomised, double-blinded study to evaluate the efficacy and safety of rezpegaldesleukin in adults with moderate-to-severe atopic dermatitis [abstract 729]. Br J Dermatol. 2024. https:\/\/doi.org\/10.1093\/bjd\/ljae266.102.","journal-title":"Br J Dermatol"},{"key":"1936_CR19","unstructured":"Nektar Therapeutics. Data from Phase 2b REZOLVE-AD and REZOLVE-AA studies presented at 2026 AAD Annual Meeting [press release]. March, 2026. https:\/\/ir.nektar.com\/news-releases\/news-release-details\/data-phase-2b-rezolve-ad-and-rezolve-aa-studies. Accessed May 2026."},{"key":"1936_CR20","unstructured":"Nektar Therapeutics. New REZOLVE-AD maintenance data demonstrate rezpegaldesleukin resulted in durable and new responses with both monthly and quarterly dosing [press release]. 10 February 2026. https:\/\/ir.nektar.com\/news-releases\/news-release-details\/new-rezolve-ad-maintenance-data-atopic-dermatitis-demonstrate. Accessed May 2026"},{"key":"1936_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae266.097","author":"D Rosmarin","year":"2024","unstructured":"Rosmarin D, Sadick N, Rodgers T, et al. A phase 2b randomised, double-blinded study to evaluate the efficacy and safety of rezpegaldesleukin in adults with severe to very-severe alopecia areata [abstract 724]. Br J Dermatol. 2024. https:\/\/doi.org\/10.1093\/bjd\/ljae266.097.","journal-title":"Br J Dermatol"},{"key":"1936_CR22","unstructured":"Nektar Therapeutics. REZOLVE-AA Phase 2b study establishes proof-of-concept in patients with severe-to-very-severe alopecia areata [press release]. 16 December 2025. https:\/\/ir.nektar.com\/news-releases\/news-release-details\/rezolve-aa-phase-2b-study-rezpegaldesleukin-establishes-proof. Accessed May 2026."},{"key":"1936_CR23","unstructured":"Nektar Therapeutics. 52-week topline results from 16-week blinded treatment extension of REZOLVE-AA demonstrate deepening of responses in severe-to-very-severe alopecia areata [press release]. 20 April 2026. https:\/\/ir.nektar.com\/news-releases\/news-release-details\/52-week-topline-results-16-week-blinded-treatment-extension. Accessed May 2026."},{"key":"1936_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.05.1165","author":"S Chaudhry","year":"2025","unstructured":"Chaudhry S, Gooderham M, Reich A, Gkalpakiotis S, Lee Z, Yu D, et al. Safety profile of rezpegaldesleukin, a selective regulatory T-cell-inducing interleukin-2 conjugate, versus placebo based on aggregate safety evaluation of 746 subjects enrolled across 9 studies [abstract 65106]. J Am Acad Dermatol. 2025. https:\/\/doi.org\/10.1016\/j.jaad.2025.05.1165.","journal-title":"J Am Acad Dermatol"},{"key":"1936_CR25","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1146\/annurev-immunol-042718-041717","volume":"38","author":"S Sakaguchi","year":"2020","unstructured":"Sakaguchi S, Mikami N, Wing JB, Tanaka A, Ichiyama K, Ohkura N. Regulatory T cells and human disease. Annu Rev Immunol. 2020;38:541\u201366. https:\/\/doi.org\/10.1146\/annurev-immunol-042718-041717.","journal-title":"Annu Rev Immunol"},{"key":"1936_CR26","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375:2335\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1610020.","journal-title":"N Engl J Med"},{"key":"1936_CR27","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","volume":"397","author":"E Guttman-Yassky","year":"2021","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397:2151\u201368.","journal-title":"Lancet"},{"issue":"18","key":"1936_CR28","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, Ohyama M, Kwon O, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687\u201399. https:\/\/doi.org\/10.1056\/NEJMoa2110343.","journal-title":"N Engl J Med"},{"key":"1936_CR29","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","volume":"401","author":"B King","year":"2023","unstructured":"King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b\u20133 trial. Lancet. 2023;401:1518\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(23)00222-2.","journal-title":"Lancet"},{"issue":"86","key":"1936_CR30","doi-asserted-by":"publisher","first-page":"eadg5506","DOI":"10.1126\/sciimmunol.adg5506","volume":"8","author":"R Tieu","year":"2023","unstructured":"Tieu R, Bhatt DL, Bhatt A, et al. Tissue-resident memory T cell maintenance during antigen persistence requires both cognate antigen and interleukin-15. Sci Immunol. 2023;8(86):eadg5506. https:\/\/doi.org\/10.1126\/sciimmunol.adg5506.","journal-title":"Sci Immunol"},{"issue":"431","key":"1936_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aam7710","volume":"10","author":"JM Richmond","year":"2018","unstructured":"Richmond JM, Strassner JP, Zapata L Jr, et al. Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo. Sci Transl Med. 2018;10(431):eaam7710. https:\/\/doi.org\/10.1126\/scitranslmed.aam7710.","journal-title":"Sci Transl Med"},{"issue":"1","key":"1936_CR32","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41423-019-0291-4","volume":"17","author":"L Chen","year":"2020","unstructured":"Chen L, Shen Z. Tissue-resident memory T cells and their biological characteristics in the recurrence of inflammatory skin disorders. Cell Mol Immunol. 2020;17(1):64\u201375. https:\/\/doi.org\/10.1038\/s41423-019-0291-4.","journal-title":"Cell Mol Immunol"},{"issue":"5","key":"1936_CR33","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/bjd\/ljad237","volume":"189","author":"J Pham","year":"2023","unstructured":"Pham J, Bhatt A, Bhatt DL, et al. Resident cutaneous memory T-cells: a clinical review of their role in chronic inflammatory dermatoses and potential as therapeutic targets. Br J Dermatol. 2023;189(5):517\u201327. https:\/\/doi.org\/10.1093\/bjd\/ljad237.","journal-title":"Br J Dermatol"},{"key":"1936_CR34","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1002\/art.22699","volume":"56","author":"B Franz","year":"2007","unstructured":"Franz B, Fritzsching B, Riehl A, et al. Low number of regulatory T cells in skin lesions of patients with cutaneous lupus erythematosus. Arthritis Rheum. 2007;56:1910\u201320. https:\/\/doi.org\/10.1002\/art.22699.","journal-title":"Arthritis Rheum"},{"key":"1936_CR35","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s00011-024-01900-w","volume":"73","author":"S Jin","year":"2024","unstructured":"Jin S, Wan S, Xiong R, et al. The role of regulatory T cells in vitiligo and therapeutic advances: a mini-review. Inflamm Res. 2024;73:1311\u201332. https:\/\/doi.org\/10.1007\/s00011-024-01900-w.","journal-title":"Inflamm Res"},{"key":"1936_CR36","unstructured":"ClinicalTrials.gov. A clinical study of MK-6194 for the treatment of vitiligo (MK-6194-007). NCT06113328. Bethesda: U.S. National Library of Medicine. Results first posted 17 March 2026. Accessed Aug 2026."},{"issue":"1","key":"1936_CR37","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jaci.2023.09.007","volume":"153","author":"SB Tsai","year":"2024","unstructured":"Tsai SB, Bhatt A, O\u2019Brien M, et al. Comparative safety of oral Janus kinase inhibitors and dupilumab in patients with atopic dermatitis: a population-based cohort study. J Allergy Clin Immunol. 2024;153(1):123\u201333. https:\/\/doi.org\/10.1016\/j.jaci.2023.09.007.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1936_CR38","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jaad.2020.08.051","volume":"86","author":"AS Halling","year":"2021","unstructured":"Halling AS, Loft N, Silverberg JI, et al. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;86(1):123\u201331. https:\/\/doi.org\/10.1016\/j.jaad.2020.08.051.","journal-title":"J Am Acad Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01936-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01936-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01936-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:03:59Z","timestamp":1793016239000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01936-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1936"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01936-2","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"8 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jo\u00e3o Domingues reports no conflicts of interest. Raj Chovatiya has served as an advisor, consultant, speaker, and\/or investigator for AbbVie, Acelyrin, Alumis, Amgen, AnaptysBio, Apogee Therapeutics, Arcutis Biotherapeutics Inc., Argenx, Astria Therapeutics Inc., Avalere Health, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Celldex CLn Skin Care, Dermavant, Eli Lilly and Company, EMD Serono, Formation Bio, Galderma, Genentech, GSK, Incyte, Johnson & Johnson, Kenvue, LEO Pharma, L\u2019Or\u00e9al, Nektar Therapeutics, Novartis, Opsidio, Pfizer Inc., RAPT, Regeneron, Sanofi, Sitryx, Takeda, TRex Bio, UCB, and Zai Lab. Raj Chovatiya is an Editorial Board member of\n                      Dermatology and Therapy\n                      . Raj Chovatiya was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Dr. Brett King has served on advisory boards and\/or is a consultant and\/or is a clinical trial investigator and\/or is on a Data Monitoring Committee for Abbvie, AltruBio Inc, Almirall, Amgen, AnaptysBio, Apogee Therapeutics, Aquestive, Aslan Pharmaceuticals, Bristol Meyers Squibb, CAGE Bio Inc, Concert Pharmaceuticals Inc, Eli Lilly and Company, Equillium, Galderma, GSK, Horizon Therapeutics, Incyte Corp, Inmagene Bio, Janssen Pharmaceuticals, LEO Pharma, Merck, Nektar, Novartis, Otsuka\/Visterra Inc, Pfizer Inc, Q32 Bio Inc, Regeneron, Sanofi Genzyme, Soterios, Sun Pharmaceutical, Takeda, TWi Biotechnology Inc, and Ventyx Biosciences Inc. He is on speaker bureaus for Abbvie, Pfizer, Regeneron, and Sanofi Genzyme. He is a scientific advisor for BiologicsMD. Tiago Torres has received consultancy and\/or speaker\u2019s honoraria from and\/or participated in clinical trials sponsored by AbbVie, Amgen, Almirall, Amgen, Apogee Therapeutics, Arena Pharmaceuticals, Biocad, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius-Kabi, Johnson & Johnson Innovative Medicine, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis, Pfizer, Samsung-Bioepis, Sanofi-Genzyme, Sandoz, STADA, and UCB. Tiago Torres is an Editorial Board member of\n                      Dermatology and Therapy\n                      . Tiago Torres was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}